期刊
ONCOLOGIST
卷 -, 期 -, 页码 -出版社
OXFORD UNIV PRESS
DOI: 10.1093/oncolo/oyad185
关键词
HER2 positive breast cancer; trastuzumab deruxtecan; trastuzumab emtansine; thrombocytopenia; romiplostim; avatrombopag
类别
The efficacy of thrombopoietin receptor agonists (TPO-RA) in improving platelet counts due to HER2-targeted antibody-drug conjugate therapy remains unknown. This article reports a case series in which TPO-RA were successfully used to treat thrombocytopenia associated with trastuzumab emtansine and trastuzumab deruxtecan therapy in breast cancer patients. All 6 patients were able to resume therapy with TPO-RA support.
Thrombopoietin receptor agonists (TPO-RA), such as eltrombopag, romiplostim, and avatrombopag, have shown efficacy in treating immune thrombocytopenia; however, their efficacy in improving platelet counts due to HER2-targeted antibody-drug conjugate therapy remains unknown. This article reports a series of cases in which TPO-RA were successfully utilized to treat such thrombocytopenia associated with ado-trastuzumab emtansine(T-DM1) and fam-trastuzumab deruxtecan (T-DXd) therapy. Trastuzumab emtansine and trastuzumab deruxtecan are widely used in breast cancer and other solid tumor malignancies. Thrombocytopenia is a common adverse event associated with the use of these agents that can lead to a treatment delay, reduction in dose intensity, and discontinuation. The role of thrombopoietin receptor agonists (TPO-RA) remains unknown in this setting. We report a case series of 6 individuals with breast cancer that experienced dose-reductions and therapy delays due to thrombocytopenia secondary to trastuzumab emtansine or trastuzumab deruxtecan therapy and received intervention with TPO-RA. All 6 were able to resume therapy with TPO-RA support.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据